With SARS-CoV-2 continuing to circulate, new oral antivirals promise to be game changers in helping to end the pandemic.
A part of the SARS-CoV-2 spike protein could prove to be its Achilles’ heel.
A biomaterials platform offers a stable center within the body for antibody development against SARS-CoV-2.
An expert review finds that booster shots for the general population are not yet necessary since vaccine efficacy against severe COVID-19 remains high.
Two vaccines in early development are stable under high temperatures and could be game changers in global vaccine equity.
COVID-19 is unlikely to be the last coronavirus to spill over to humans. Scientists are working to make a universal vaccine to combat future outbreaks.
Data reported through a smartphone app provides the first detailed description of COVID-19 in symptomatic school-aged children.
Citing concern over vaccine efficacy against emerging variants, Pfizer seeks approval for a third booster, but many are not yet convinced it is necessary.
Small clinical trial has found that metabolic activators can improve recovery, liver health, and markers of inflammation in patients with COVID-19.
The protein-based vaccine has been highly anticipated, showing high efficacy against variants of concern.